Amanda Braithwaite

发表

17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

D. Selley, J. Streicher, W. Dewey, 2016, ACS chemical neuroscience.

6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.

W. Dewey, H. Akbarali, E. Bilsky, 2012, Bioorganic & medicinal chemistry letters.

Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

J. Streicher, E. Bilsky, Yunyun Yuan, 2014, European journal of pharmacology.